Navigation Links
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter financial results and Nycomed's decision whether to proceed with ex-U.S. development and commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007. NPS expects to receive notification from Nycomed at the end of this month regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM) (teduglutide) outside North America. The announcement will be followed by a conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles, president and CEO, and other members of the NPS executive team.

To participate in the conference call, dial (866) 770-7051 and use passcode 53288322. International callers may dial (617) 213-8064, using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site (http://www.npsp.com).

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 16038876, until midnight EST, November 15, 2007. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available on the NPS website for the same period of time.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...E, Gabon, December 2 , - ...blem and Heritage" , Coinciding with the ...the,Gabonese Republic is hosting an international ...afeguarding biological resources in Africa. The,co...leaders, ministers,scientific experts, private co...
(Date:12/2/2009)...E, Dec. 2 S*BIO Pte Ltd today anno...hibitor, SB1518, at The American Society of Hemato...eans. ,, Data will be presented on the clinical... SB1518 detailing its safety, tolerability and pha...se levels ranging from 100 to 600 mg. These doses ...
(Date:12/2/2009)...I, Dec. 2 /PRNewswire-Asia/ -- The world is going ...l and uncertainty is part of many,businesses and i...as been,relatively immune to the economic downturn... During the midst of the difficult times this y...n inaugurated an R&D center in Shanghai, the l...
(Date:12/1/2009)..., Nev., Dec. 1 PDL BioPh...revenue guidance for the fourth quarter ended Dece...pared with $69 million for the fourth quarter of 2...he first of two installment payments of $12.5 mill... 2008 results was a one-time $1.8 million payment ...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...Officer and James Weaver as Chairman, WALTHAM, Ma...I ) announced today that Thomas Gerson has been na... also appointed James Weaver as,Chairman of the Bo...ined,the company as Vice President, Research and D...erleukin," said Thomas Curran,Interim Chief Execut...
.... ET; 8:00 a.m. PT, VANCOUVER and SAN DIEGO, CA, ...: MGI; OTC: MGIFF), a clinical-stage developer of ...nce call and webcast on Tuesday,September 11, 2007...ial,results for the first fiscal quarter ended Jul...lso be provided. To participate in the conference,...
...try Readiness and Questions Fiscal and So...SHINGTON, Sept. 6 Expensive biologic,medicines ar... patents,expire, and generic companies stand ready...ow is the time to pass legislation enabling the U.... abbreviated regulatory,pathway for safe, pure and...
Other Biology Technology:Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2Biogenerics Will Save Billions, Says Hospira CEO 2Biogenerics Will Save Billions, Says Hospira CEO 3Biogenerics Will Save Billions, Says Hospira CEO 4
(Date:12/3/2009)...an Andel Research Institute (VARI) researchers hav...sic acid (ABA) works at the molecular level to hel... drought and cold. Their findings, published in t...t thrive in harsh environments around the world an...d also have implications for stress disorders in h...
(Date:12/3/2009)... levels for the past three years in the tropospher...al area near Valladolid. The results, which are th...ow that the levels rose "significantly" between 20... meteorologists have been trying to find out about...volved in the troposphere over various urban and r...
(Date:12/2/2009)...ondhand cigarette smoke have an increased risk of ...never smoked. , Results of this study are publi...ion , a journal of the American Association for Ca...in the December issue. , This year alone, more ... cancer; more than 159,000 will die from it and so...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3CO2 levels rising in troposphere over rural areas 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2New type of adult stem cells found in the prostate may be involved in prostate cancer development 56649 1New type of adult stem cells found in the prostate may be involved in prostate cancer development 56649 2Ancient oceans offer new insight into the origins of animal life 9852 1Ancient oceans offer new insight into the origins of animal life 9852 2Cements basic molecular structure finally decoded 9850 1Cements basic molecular structure finally decoded 9850 2Cements basic molecular structure finally decoded 9850 3
...s a dramatic improvement in cheap solar cells now ...corn-ball design tiny kernels clumped into much l...y of Washington are able to manipulate light and m... energy to electricity. The findings will be prese...of the American Chemical Society. , "We think th...
...lable in German . , , Halle/Saale. Migratory bir...stance. These are the findings of a team of ornith...burg, the Ornithological Society in Bavaria and th...), writing in the Journal of Ornithology. The scie...birds from the leaf-warbler and thrush families t...
...ril) at the UK National Stem Cell Network Annual S... from Cardiff University describes his work to inv...em cells to repair the intestine. Together with hi...sgow, he has found that if things go wrong and a c...is normal function of controlling the adult stem c...
Other Biology News:Popcorn-ball design doubles efficiency of dye-sensitized solar cells 2Flying off course 2Flying off course 3Stem cells and cancer: cancer pathways that also control the adult stem cell population 2
...nd PowerPac basic power supply are used for submer...s in agarose gels. The Mini-Sub cell GT cell inclu... a 7 x 7 cm UV-transparent gel tray with fluoresce...height combs (8- and 15-well). The PowerPac basic ...
...owerPac basic power supply are used for submerged ... agarose gels. This Model 96 cell includes a buffe...fluorescent ruler, and a gel caster. The PowerPac ...s output of 10-300 V, 4-400 mA, and 75 W. Power co...
...PowerPac basic power supply are used for submerged...n agarose gels. This Model 192 cell includes a buf...h fluorescent ruler, and a gel caster. The PowerPa...des output of 10-300 V, 4-400 mA, and 75 W. Power ...
...ac 3000 system, 220-240 V, is used for nucleic aci...format. The system includes the modular Sequi-Gen ...ating nucleic acids with single base-pair resoluti...sembly (IPC and bonded inner glass plate, outer gl...
Biology Products: